Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus-associated refractory cerebral vasculitis induces immune tolerance

Melek Yalcin Mutlu; Jochen Wacker; Koray Tascilar; Jule Taubmann; Bernhard Manger; Gerhard Krönke; Georg Schett; David Simon

doi:10.1093/rheumatology/keac393

Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus-associated refractory cerebral vasculitis induces immune tolerance

Rheumatology (Oxford). 2023 Feb 1;62(2):e21-e23. doi: 10.1093/rheumatology/keac393.

Authors

Melek Yalcin Mutlu^{1

2}, Jochen Wacker^{1

2}, Koray Tascilar^{1

2}, Jule Taubmann^{1

2}, Bernhard Manger^{1

2}, Gerhard Krönke^{1

2}, Georg Schett^{1

2}, David Simon^{1

2}

Affiliations

¹ Department of Internal Medicine 3.
² Deutsches Zentrum fuer Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

PMID: 35801920
DOI: 10.1093/rheumatology/keac393

No abstract available

Publication types

Letter

MeSH terms

Humans
Immune Tolerance
Lupus Erythematosus, Systemic* / complications
Lupus Erythematosus, Systemic* / drug therapy
Vasculitis, Central Nervous System* / drug therapy